Skip to content
Search

Latest Stories

Insys founder Kapoor jailed for 66 months over scheme to boost opioid sales

John Kapoor, the founder of Insys Therapeutics Inc, on Thursday, was sentenced to 66 months in prison for his role in a bribery and fraud scheme that contributed to the U.S. opioid crisis.

Kapoor, 76, is now the highest-ranking pharmaceutical executive to be sentenced in a case linked to the opioid crisis. His was the harshest sentence in a case in which several former Insys executives will go to prison.


Forfeiture and restitution in Kapoor's case still need to be determined. Government prosecutors are asking for about $113 million (£86.3 million) in forfeiture from a man who grew up poor in India, but became a billionaire before founding Insys.

During a hearing that lasted nearly two hours, U.S. prosecutors asked U.S. District Court Judge Allison D. Burroughs to sentence Kapoor to 15 years in prison. Some victims also asked her to give Kapoor a maximum penalty.

Victims told the judge they were prescribed a highly addictive opiate that they did not need. They described losing their teeth and being unable to put two thoughts together as they lived in a haze of addiction. One victim told the judge Kapoor should be treated as a drug trafficker.

Burroughs said her lesser sentence took into account his central role in the crime, his many good works as a philanthropist and his age.

Nevertheless, Kapoor is due to serve significantly more prison time than other former senior Insys executives convicted in the bribery and fraud scheme.

On Wednesday, former Insys Chief Executive Michael Babich, 43, was sentenced to 30 months in prison. Babich last year pleaded guilty to conspiracy to commit mail fraud and wire fraud and agreed to cooperate with the government.

Over several days of testimony, Babich had described the inner workings of the conspiracy in detail. The trial resulted in the conviction of Kapoor, as well as the company's vice president of managed markets, Michael Gurry, national director of sales Richard Simon, and two Insys regional sales directors, Joseph Rowan and Sunrise Lee.

Subsys, the company's fentanyl-based medication, was approved to treat intense pain in cancer patients.

But Babich and others would identify high prescribers of opioid treatments and pay bribes or kickbacks to get them to broaden Subsys uses, increasing the number of new prescriptions, as well as dosage prescribed and units sold.

Assistant U.S. Attorney Nathaniel Yeager described Kapoor as the linchpin of the scheme.

"It was a top-down conspiracy run by John Kapoor," Yeager told the judge.

Burroughs said she was not convinced Kapoor was the linchpin of the operation but acknowledged he was a central player.

Kapoor, who served as the Chandler, Arizona-based drugmaker's chairman and later chief executive after Babich stepped down, apologized to the victims in the courtroom.

"I am heartbroken by the words of the patients," Kapoor said. "I sincerely apologize to them."

From 1999 to 2017, some 400,000 people died from overdoses involving an opioid, including prescription and illicit drugs, according to U.S. health officials.

(Reuters)

More For You

Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Asda pharmacy launches UK’s first adult earache service

Asda makes ear health more accessible for everyone

gettyimages

Asda pharmacy launches £25 adult earache service

British supermarket chain Asda has launched the “UK’s first” adult earache service, aiming to reduce the burden on NHS services by eliminating the need for a GP appointment.

Priced at £25, the service allows patients aged 18 and over to book same-day appointments with qualified Asda pharmacists at any of its 226 pharmacies in England.

Keep ReadingShow less
Cat Smith MP Leads Call for Urgent Action

Health minister Wes Streeting

Pic credit: Getty Images

Urgent review into medicine shortages needed, ministers tell Streeting

Health minister Wes Streeting has been urged by 45 MPs to call an urgent review into medicine shortages that is impacting the health and safety of patients.

The news comes on the back of the death David Compton, a 44-year-old man who fell and suffered a heart attack which has been linked to him not being able to get medication for epilepsy.

Keep ReadingShow less